OIPE JC131
AUG 0 1 2005
PATENT & TRADEMARK OFFICE

09/578239

Copy

RLL-5.4DIV

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicants:	Anand *et al.*	
Patent No.:	6,812,344 B1	Examiner: Wright, Sonya N.
Grant Date:	November 2, 1004	Group Art Unit: 1626

For: 1-(4-ARYLPIPERAZIN-1-YL)- ω-[N-(α,ω-DICARBOXIMIDO)]-ALKANES USEFUL AS UROSELECTIVE α1-ADRENOCEPTOR BLOCKERS

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 27, 2005.

Kim Campbell

Certificate
AUG 05 2005
of Correction

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION

PURSUANT TO 35 U.S.C. 254 & 35 U.S.C. 255

Dear Sirs:

Applicants respectfully request a Certificate of Correction be issued incorporating the corrections as presented on the attached "Certificate of Correction" form.

This request is being issued pursuant to 35 U.S.C. 254 – Certificate of Correction of Patent and Trademark Office mistake & 35 U.S.C. 255 – Certificate of Correction of applicant's mistake. The basis for this request is typographical errors that have been made by both the USPTO and applicant.

Authorization is hereby given to charge any fees associated herewith to Deposit Account No. 50-0912.

Respectfully submitted,

Anand *et al.*

Dated: July 27, 2005

By: _____
George E. Heibel
Reg. No., 42,648
Customer No. 26815

AUG 9 - 2005

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : **6,812,344 B1**

DATED : **November 2, 2004**

INVENTOR(S) : **Anand et al.**

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 1, Title - "DICARBOXIMIDOL)" should read "DICARBOXIMIDO)"
Page 1, Abstract - "prostratic" should read "prostatic"
Column 1, Line 2 - "DICARBOXIMIDOL)" should read "DICARBOXIMIDO)"
Column 1, Line 31 - "prostrate" should read "prostate"*
Column 2, Line 62 - "penyl" should read "phenyl"
Column 2, Line 62 - "Therapeuetica" should read "Therapeutica"
Column 3, Line 12 - "2-[3-4aryi-"should read "2-[3-(4-aryl-"
Column 3, Line 14 - "pynolidinediones" should read "pyrrolidinediones"
Column 3, Line 15 - "of N4-aryl" should read "of N-(N4-aryl"
Column 3, Line 15 - "-piperozinyhnethyl)4-" should read "-piperozinylmethyl)-4-"
Column 3, Line 17 - "of N(N4-" should read "of N-(N4-"
Column 3, Line 49 - "piperazine" should read "piperazin"
Column 3, Line 51 - "antisehemic" should read "antischemic"
Column 3, Line 57 - "60 1D" should read " 1D"
Column 3, Line 63 - "requirement A for" should read "requirement for"
Column 4, Line 1 - "the" should read "than"
Column 4, Line 26 - "OC2H5" should read "OC2H5"
Column 4, Line 27 - "C2H5" should read "C2H5"
Column 4, Line 57 - "Z" R'1" should read "Z', R1" * (both)
Column 4, Line 64 - "piperazine" should read "piperazin"
Column 4, Line 66 - "(2-Methox phenyl)piper azin-1-yl] should read "(2-Methoxyphenyl)piperazin-1-yl]
Column 5, Line 1 - "piperazine" should read "piperazin"
Column 5, Line 3 - "piperazine" should read "piperazin"
Column 5, Line 5 - "piperazine" should read "piperazin"
Column 5, Line 7 - "piperazine" should read "piperazin"
Column 5, Line 8 - "5dioxopyrrolidin" should read "5-dioxopyrrolidin"
Column 5, Line 9 - "4(2" should read "4-(2"
Column 5, Line 9 - "piperazine" should read "piperazin"
Column 5, Line 10 - "dioxoyrrolidin- 1-yl" should read "dioxoyrrolidin-1-yl"
Column 5, Line 13 - "-Metboxyphenyl)" should read "-Methoxyphenyl)"
Column 5, Line 13 - "piperazine" should read "piperazin"
Column 5, Line 13 - "-4(2" should read "-4-(2"
Column 5, Line 15 - "[1-4" should read "[-4-"
Column 5, Line 15 - "-Metboxyphenyl)" should read "-Methoxyphenyl)"
Column 5, Line 15 - "piperazine" should read "piperazin"
Column 5, Line 15 - "-2(2" should read "-2-(2"
Column 5, Line 16 - "5diosopyrrolidin" should read "5-dioxopyrrolidin"

MAILING ADDRESS OF SENDER: **Jayadeep R. Deshmukh, Esq.**
Customer No. 26815

PATENT NO. **6,812,344 B1**

No. of additional copies

→ 5

AUG 9 – 2005

P15/REV02

CERTIFICATE OF CORRECTION

Column 5, Line 17– "piperazine" should read "piperazin"
Column 5, Line 17 – "]-3(2" should read "]-3-(2"
Column 5, Line 19 – "-[4(4-"should read "-[4-(4-"
Column 5, Line 19 – "piperazine" should read "piperazin"
Column 5, Line 19 – "]-3(2" should read "]-3-(2"
Column 5, Line 20 - "5dioxopyrrolidin" should read "5-dioxopyrrolidin"
Column 5, Line 20 – "-1-ylopropane" should read "-1-yl)propane"
Column 5, Line 21 – "piperazine" should read "piperazin"
Column 5, Line 23 – "-[4(4-"should read "-[4-(4-"
Column 5, Line 23 – "piperann-1yl" should read "piperazin-1-yl"
Column 5, Line 25 – "piperazine" should read "piperazin"
Column 5, Line 26 – "dioxopiperidia-1-yl)propant" should read "dioxopiperidin-1-yl)propane"
Column 5, Line 27 – "1-4-(3" should read" 1-[4-(3"
Column 5, Line 27 – "piperazine" should read "piperazin"
Column 5, Line 29 – "piperazine" should read "piperazin"
Column 5, Line 31 – "piperazine" should read "piperazin"
Column 5, Line 32 – "piperazine" should read "piperazin"
Column 5, Line 32 – "6dioxopiperidin" should read "6-dioxopiperidin"
Column 5, Line 33 – "6-dioxpiperidin" should read "6-dioxopiperidin"
Column 5, Line 35 – "piperazine -1-yl" should read "piperazin-1-yl" ?
Column 5, Line 37 – "-[4(3,4-" should read "-[4-(3,4-"
Column 5, Line 37 – "piper -1-yl]-3(2" should read "piperazin-1-yl]-3-(2"
Column 6, Line 1 – "-[4(2-Pyrimidyi)" should read "-[4-(2-Pyrimidyl)"
Column 6, Line 1– "piperazine" should read "piperazin"
Column 6, Line 1 – "2,6diozopiperidin-"should read "2,6-dioxopiperidin"
Column 6, Line 3 – "piperazine" should read "piperazin"
Column 6, Line 4 – "6dioxopiperidia" should read "6-dioxopiperidin"
Column 6, Line 5 – "1-[4(4-" should read "1-[4-(4-"
Column 6, Line 5 – "piperazine" should read "piperazin"
Column 6, Line 6 – "6dioxopiperidin-1-yl)propine" should read "6-dioxopiperidin-1-yl)propane"
Column 6, Line 7 – "piperazine" should read "piperazin"
Column 6, Line 7 – "]-(2,6-" should read "]-4-(2,6-"
Column 6, Line 8 – "dioxpiperidin" should read "dioxopiperidin"
Column 6, Line 9 – "piperazine" should read "piperazin"
Column 6, Line 9 & 10 – "[2-ioxo-3-phenyt-pyrolidin -1-yl]" should read "[2,5-dioxo-3-phenyl-pyrolidin-1-yl]"
Column 6, Line 11 – "(Phenyo)" should read ""(Phenyl)"
Column 6, Line 11 – "-3-2,5-" should read "-3-[2,5-"

CERTIFICATE OF CORRECTION

Column 6, Line 22 – "for C) Schemes" should read "for Schemes"
Column 6, Line 27 – "R4" should read "R_4"
Column 6, Line 27 – "n Z," should read "n, Z,"
Column 6, Line 27 – "Z',. Q" should read "Z', Q"
Column 6, Line 29 – "(α, ω-" should read "α, ω-"
Column 6, Line 30 – "arylpiperazin- 1-yl" should read "arylpiperazin-1-yl"
Column 6, Line 33 – "1(4-" should read "1-(4-"
Column 6, Line 34 – "odicarboximido" should read "dicarboximido"
Column 7, Line 2 – "Formula H" should read "Formula II"
Column 7, Line 31 – "ωdihaloalkanes" should read "ω-dihaloalkanes"
Column 7, Line 31 – "1(ω-" should read "1-(ω-"
Column 7, Line 40 – "tetrabutylammoniutm" should read "tetrabutylammonium"
Column 8, Line 30 – "piperaies" should read "piperazines"
Column 8, Line 31 – "synthesizd" should read "synthesized"
Column 8, Lines 32 & 33 – V. 21, C) p. 1301" should read "V. 21, p. 1301"
Column 8, Line 34 – "Aggarwat" should read "Aggarwal"
Column 8, Line 38 – "Pharmacolopical: should read "Pharmacological"
Column 8, Line 42 – "aays" should read "assays"
Column 9, Lines 1 & 2 – "characterizton" should read" characterization"
Column 9, Line 5 - "in vitro" should read "*in vitro*"
Column 9, Line 12 – "manuals" should read "mammals"
Column 9, Line 22 – "parenterally. in" should read "parenterally in"
Column 9, Line 23 – "phanuceutcal" should read " pharmaceutical"
Column 9, Line 24 – "[4(" should read "[4-(("
Column 9, Line 25 – "piperazine" should read "piperazin"
Column 9, Line 25 – "piperazine" should read "piperazin"
Column 9, Line 27 – "]4-" should read "]-4-"
Column 9, Line 29 – "6dioxopiperidin" should read "6-dioxopiperidin"
Column 9, Line 31 – ") Pharmaceutically" should read "Pharmaceutically"
Column 9, Line 38 – "bisruethylene salicylic" should read "bismethylene salicylic"
Column 9, Line 47 – "fimctional" should read "functional"
Column 9, Line 48 – "in vivo" should be "*in vivo*"
Column 9, Line 59 – "rcipients" should read "excipients"
Column 9, Line 64 – "compounds. of" should read "compounds of"
Column 10, Line 1 – "piperazine" should read "piperazin"
Column 10, Line 2 – "-3[2" should read "-3-[2"
Column 10, Line 2 – "5dioxopyrroldin" should read "5-dioxopyrrolidin"
Column 10, Line 6 – "moil" should read "mmol"
Column 10, Line 6 – "-fluorophenyl) -piperazine-1-yl]" should read "-fluorophenyl)-piperazin-1-yl]"

CERTIFICATE OF CORRECTION

Column 10, Line 10 – "in vacuo" should read "*in vacuo*"
Column 10, Line 13 – "mnl" should read "ml"
Column 10, Line 14 – "in vacuo" should read "*in vacuo*"
Column 10, Line 18 – "-3-[(4" should read "-3-[4-(4-"
Column 10, Line 18 – "succiznic" should read "succinic"
Column 10, Line 23 – "in vacuo" should read "*in vacuo*"
Column 10, Line 27 – "flash ii silica" should read "flash silica"
Column 10, Line 30 – "3 Scheme- III" should read "Scheme-III"
Column 10, Line 31 – "5dioxopyrrolidin" should read "5-dioxopyrrolidin"
Column 10, Line 34 – "N-direthylformamide" should read "N-dimethylformamide"
Column 10, Line 43 – "[4(4-" should read "[4-(4-"
Column 10, Line 44 – "piperazine" should read "piperazin"
Column 10, Line 44 – "-3 2,5" should read "-3-(2,5"
Column 10, Line 50 – "piperazine" should read "piperazin"
Column 10, Line 51 – "propane in" should read "propane"
Column 10, Line 53 – "1b Scheme-I" should read "Scheme-I"
Column 10, Line 54 – "piperazine" should read "piperazin"
Column 10, Line 58 – "stirrig" should read "stirring"
Column 10, Line 61 – "(2X50)" should read "(2X50 ml),"
Column 10, Line 64 – "chloroforin" should read "chloroform"
Column 11, Line 1 – " 1choloro" should read "1-chloro"
Column 11, Line 3 - "rnnol" should read "mmol"
Column 11, Line 5 - "dirnethylformamide" should read "dimethylformamide"
Column 11, Line 14 - "dixopyrrolidin" should read "dioxopyrrolidin"
Column 11, Line 17 – "tetrabutylammoniwn" should read "tetrabutylammonium"
Column 11, Line 18 – "methox phenyl" should read "methoxyphenyl"
Column 11, Line 18 – "piperazine" should read "piperazin"
Column 11, Line 19 – "]4,[" should read "]-3-["
Column 11, Line 21 – "1chloro" should read "1-chloro"
Column 11, Line 21 – "2,5dioxopyrrolidin" should read "2,5-dioxopyrrolidin"
Column 11, Line 23 – "minol)" should read "mmol)"
Column 11, Line 25 – "nmol" should read "mmol"
Column 11, Line 31 – "[4(2-" should read "[4-(2-"
Column 11, Line 32 – "piperizine 1-yl]4" should read "piperazin-1-yl]-4"
Column 11, Line 32 – "dioxopyrrolid" should read "dioxopyrrolidin"
Column 11, Line 38 – "Chloro4-" should read "Chloro -4-"
Column 11, Line 38 – "doxopyrrolidin" should read "dioxopyrrolidin"
Column 11, Line 41 – "tetrabutylaminonium" should read "tetrabutylammonium"
Column 11, Line 42 – "-14-" should read "-[4-"
Column 11, Line 42 – "piperazine" should read "piperazin"

CERTIFICATE OF CORRECTION

Column 11, Line 46 – "smol)" should read "mmol)"
Column 11, Line 46 – "piperazine" should read "piperazin"
Column 11, Line 46 – "yl]-3-" should read "yl]-3-"
Column 11, Line 48 – "mnmol" should read "mmol"
Column 11, Line 49 – "aeetone" should read "acetone"
Column 11, Line 54 – "tide" should read "title"
Column11, Line 60 – "chloro3-2,6doxopiperidin" should read "chloro-3-(2,6-dioxopiperidin"
Column 11, Line 61 – "1-methoxyphenyl)" should read "1-(2-methoxyphenyl)"
Column 11, Line 67 – "tover" should read "over"
Column 12, Line 3 – "rnmethaol" should read "methanol"
Column 12, Line 12 – "[4(4-" should read "[4-(4-"
Column 12, Line 15 – "piperazine" should read "piperazin"
Column 12, Line 15 & 16 – "-342,5dioxopyrrolidin" should read "-3-(2,5-dioxopyrrolidin"
Column 12, Line 17 – "piperazine" should read "piperazin"
Column 12, Line 18 – "diopyrrolidin" should read "dioxopyrrolidin"
Column 12, Line 20 – "piperazine -1-yl]-3(2,5dioxopyrrolidin" should read "piperazin-1-yl]-3-(2,5-dioxopyrrolidin"
Column 12, Line 22 – "(3Chloropheuyl)" should read "(3-Chlorophenyl)"
Column 12, Line 22 & 23 – "1-3) 2,5dioxopyrrolidin" should read "-3-(2,5-dioxopyrrolidin"
Column 12, Line 23 – "hydrochlonde" should read "hydrochloride"
Column 12, Line 25 – "piperazine" should read "piperazin"
Column 12, Line 27 – "[4-3,4-" should read " [4-(3,4-"
Column 12, Line 27 – "piperazine" should read "piperazin"
Column 12, Line 27 & 28 – "-3(2,5dioxopyrrolidin" should read "-3-(2,5-dioxopyrrolidin"
Column 12, Line 30– "piperazine" should read "piperazin"
Column 12, Line 30 – "(2,5dioxopyrrolidin" should read "(2,5-dioxopyrrolidin"
Column 12, Line 32 – "1-[4(2-" should read "1-[4-(2"
Column 12, Line 32 – "piperazine" should read "piperazin"
Column 12, Line 33 – "m.p. 218-220° C." should read "m.p. 219-220° C."
Column 12, Line 35 – "piperazine" should read "piperazin"
Column 12, Line 35 & 36 – "dioxpyrrolidin" should read "dioxopyrrolidin"
Column 12, Line 37 – "[4-3-Methoyphenyl" should read "[4-(3-Methoxyphenyl"
Column 12, Line 37 – "piperazine" should read "piperazin"
Column 12, Line 37 – "-3(2,5 –dioxopyrroldin" should read "-3-(2,5-dioxopyrrolidin"
Column 12, Line 40 – "piperazine" should read "piperazin"
Column 12, Line 43 – "piperazine" should read "piperazin"
Column 12, Line 43 – "-3(2,6-" should read "-3-(2,6-"
Column 12, Line 44 – "205-207° C" should read "206-210° C"
Column 12, Line 46 – "1-[(4-4-" should read "1-[4-(4-"
Column 12, Line 46 – "piperazn" should read "piperazin"
Column 12, Line 48 – "(4Chlorophenyl)" should read "(4-Chlorophenyl)"

CERTIFICATE OF CORRECTION

Column 12, Line 50 – "piperazine" should read "piperazin"
Column 12, Line 53 – "piperazine" should read "piperazin"
Column 12, Line 56 – "(2Methylphenyl)" should read "(2-Methylphenyl)"
Column 12, Line 56 – "piperazine" should read "piperazin"
Column 12, Line 56 – "-3(2,6-dioxpiperidin-" should read "-3-(2,6-dioxopiperidin-"
Column 12, Line 58 – "(Pyrdyl)piperazin-1-yl-" should read "(2-Pyridyl)piperazin-1-yl)-"
Column 12, Line 58 – "diozopiperidin" should read "dioxopiperidin"
Column 12, Line 60 – "piperazine" should read "piperazin"
Column 12, Line 60 – "-3 -" should read "-3-" *
Column 12, Line 61 – "dioxopiperidin -1" should read "dioxopiperidin-1" *
Column 12, Line 63 – "piperazine" should read "piperazin"
Column 12, Line 64 – "dioxopiperidinl" should read "dioxopiperidin"
Column 12, Line 64 – "hydro-chloride" should read "hydrochloride"
Column 12, Line 66 – "piperazine" should read "piperazin"
Column 13, Line 1– "piperazine" should read "piperazin"
Column 13, Line 4 – "1-[-(4-4-" should read "1-[4-(4-"
Column 13, Line 4 – "piperazine" should read "piperazin"
Column 13, Line 7 – "piperazine" should read "piperazin"
Column 13, Line 7 – "]4-(" should read "]-4-("
Column 13, Line 8 – "6dioxopiperidin" should read "6-dioxopiperidin"
Column 13, Line 10 – "piperazine" should read "piperazin"
Column 13, Line 19 – "assays. (RBA's)" should read "assays (RBA's)"
Column 13, Line 22 – "αa_{1A}" should read "α_{1A}"
Column 14, Line 2 – "against" should read "agonist"
Column 14, Line 5 – "vistar" should read "wistar"
Column 14, Line 7 – "$CaCl_2$;" should read "$CaCl_2$ 2.5;"
Column 14, Line 30 – "Muscannic" should read "Muscarinic"
Column 14, Line 66 – "β_B" should read "β_1"
Column 15, Line 21 – "Antih Pertensive" should read "Antihypertensive"
Column 15, Line 29 – "gtkg" should read "g/kg"
Column 15, Line 30 – "Statharn" should read "Statham"
Column 15, Line 62 – "Nornotensive" should read "Normotensive"
Column 16, Line 60 – "digitalpressure" should read "digital pressure"

US006812344B1

(12) **United States Patent**
Anand et al.

(10) **Patent No.: US 6,812,344 B1**
(45) **Date of Patent: Nov. 2, 2004**

(54) **1-(4-ARYLPIPERAZIN-1-YL)-ω-[N-(α,ω-DICARBOXIMIDOL)]-ALKANES USEFUL AS URO-SELECTIVE α1-ADRENOCEPTOR BLOCKERS**

(75) Inventors: **Nitya Anand**, Lucknow (IN); **Neelima Sinha**, Noida (IN); **Sanjay Jain**, Noida (IN); **Anita Mehta**, Gurgaon (IN); **Anil Kumar Saxena**, Lucknow (IN)

(73) Assignee: **Ranbaxy Laboratories Limited**, Delhi (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/578,239**

(22) Filed: **May 24, 2000**

Related U.S. Application Data

(62) Division of application No. 09/120,265, filed on Jul. 21, 1998, now Pat. No. 6,083,950.

(30) **Foreign Application Priority Data**

Nov. 13, 1997 (IN) 3261/DEL/97
Nov. 13, 1997 (IN) 3260/DEL/97

(51) **Int. Cl.**[7] **C07D 401/06**; C07D 403/06
(52) **U.S. Cl.** **544/360**; 544/372
(58) **Field of Search** 544/360, 372

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,922,788 A		1/1960	Parcell et al.	
3,637,705 A		1/1972	Horrom et al.	
4,524,206 A	*	6/1985	New et al.	544/230
5,403,847 A		4/1995	Gluchowski et al.	514/318
5,508,306 A		4/1996	Chiu et al.	514/524
5,578,611 A		11/1996	Gluchowski et al.	514/318
5,780,485 A		7/1998	Gluchowski et al.	514/318
5,990,128 A		11/1999	Gluchowski et al.	514/318
6,015,819 A		1/2000	Gluchowski et al.	514/318
6,057,350 A		5/2000	Patane et al.	514/376

FOREIGN PATENT DOCUMENTS

FR	1381425	4/1973
IN	496/Del/95	8/1995

OTHER PUBLICATIONS

Wu, Yao-Hua, et al., "Psychosedative Agents. N-(4-Phenyl-1-Piperazinylalkyl)-Substituted Cyclic Imides", J. Med. Chem., vol. 12 (1969) pp. 876-881.*

Ishizumi, et al., "Synthesis and Anxiolytic Activity of N-Substituted Cyclic Imides . . . (Tandospirone) and Related Compounds", Chem. Pharm. Bull., vol. 39, No. 9 (1991) pp. 2288-2300.*

Additions and Corrections, J. Med. Chem, John Wityak. 1997, 40, 1292.

Synthesis and Pharmacology of some 2-[3(-Aryl-1-piperazinyl) propyl]-1 H-benz[isoquinolin-1,3(2H)-dioaes/2,5-pyrrolidinediones, B. M. Khadilkar, J. Indian Chem. Soc., 1986, VLXIII, 529-530.

N-(N4-Aryl-N piperazinylmethyl)-4-(4-methoxyphenyl)-piperidine-2,6-diones: CNS Depressants, S. D. Samant, Ind. Chem. Soc., 1978, 819-821.

Substituted trifluyoromethyl phenyl piperazines as anorectic agents, Eur. J. Med. Chem. Chimica Therapeutica, peter E. Cross, 1977, 12, No. 2, 173-176.

Synthesis and Pharmacology of N-(N4-Aryl-N1- Piperazinylalkyl) P{hthalimides: CNS Depressants, S.D. Samant, J. Indian Chem. Soc., vol. LVI, Oct. 1979, 1002-1005.

Synthesis and Quantitative Structure-Activity Relationships of Some Antibacterial 3-Formylrigamycin SV N-(4-Substituted phenyl) piperazinoacethydrazones, Journal of Medicinal Chemistry, 1978, vol. 21, No. 12, 1301.

Synthesis & Biological Activities of 3-Substituted I-Aryloxyaminopropanes, Shiv K. Agarwal, Indian Journal of Chemistry, vol. 21B, May 1982, 435-439.

Protein Measurement with the Folin Phenol Reagent, Oliver H. Lowry, J. Biol. Chemistry, V. 193, 265-275.

* cited by examiner

Primary Examiner—Deborah C. Lambkin
Assistant Examiner—Sonya Wright
(74) *Attorney, Agent, or Firm*—Jayadeep R. Deshmukh, Esq.; George Heibel, Esq.; William Hare, Esq.

(57) **ABSTRACT**

The present invention relates to certain novel piperazine derivatives having protracted uro-selective α_1-adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treating benign prostratic hyperplasia (BPH). This invention also relates to methods for making the novel compounds, pharmaceutical compositions containing the compounds, and methods of treating benign prostatic hyperplasia using the compounds.

4 Claims, No Drawings

PALM INTRANET

Day : Tuesday
Date: 8/9/2005
Time: 16:05:12

Correspondence Address for 09/578239

Customer Number	Contact Information	Address
26815	Telephone: (609)720-5608 Fax: (609)514-9779 E-Mail: No E-Mail Address	RANBAXY INC. 600 COLLEGE ROAD EAST SUITE 2100 PRINCETON NJ 08540

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity Data | Foreign Data

Search Another: Application# [] Search **or Patent#** [] Search

PCT / [] / [] Search **or PG PUBS #** [] Search

Attorney Docket # [] Search

Bar Code # [] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

AUG 9 – 2005